InNexus Biotechnology Inc. is developing a new generation of monoclonal antibodies termed SuperAntibodies (SAT). The Company is exploiting SAT to generate second generation diagnostic and therapeutic antibodies. InNexus is focused on marketing the SAT to the pharmaceutical community for the purpose of entering into licensing agreements.
1400 - 400 Burrard Street
Vancouver, BC V6C 3G2